Clinical trials: Rejection of Renal Transplant
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Kidney Transplantation
Impact of HLA Evolutionary Divergence and HLA Donor-recipient Molecular Mismatches on Kidney Allograft Rejection
The Human Leucocyte Antigen (HLA) system is pivotal in kidney transplant rejection. In-silico methods such as HLA eplet mismatches and PIRCHE-II scores have emerged to refine HLA immunogenicity assessment and stratify patients…
- Trial name
- NCT06436586
- Testing
- No intervention
- Where
- France
- Volunteers
- 5,159 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Kidney Transplant Rejection, Pediatric Kidney Disease
Pediatric Induction Therapy in Kidney Transplantation
The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children.
- Trial name
- PINK (NCT06087003)
- Testing
- Basiliximab Injection, rabbit ATG
- Where
- 5 sites in China
- Volunteers
- 958 people
- Sponsor
- Gang Chen
Kidney Transplant Rejection, End Stage Renal Disease
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
- Trial name
- NCT05987527
- Testing
- Blood sample
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 11 people
- Sponsor
- Sangamo Therapeutics
Kidney Transplant Rejection, Kidney Transplantation
Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Main objective: To design a precision risk stratification system that predicts individual risk of rejection
- Conditions
- Kidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis
- Trial name
- EU-TRAIN (NCT03652402)
- Testing
- kidney transplantation
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 558 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant Failure and Rejection
BIOtechnology Applied to Renal TRansplantation With IMmunobiogram
Immunobiogram (IMBG) is a novel in vitro diagnostic bioassay developed by Biohope Scientific Solutions for Human Health SL, that allows to measure the pharmacodynamic response to individual immunosuppressive drugs in patients…
- Trial name
- BIOTRAIM (NCT05816486)
- Testing
- Immunobiogram
- Where
- 15 sites in Brazil, France and 3 more
- Volunteers
- 443 people
- Sponsor
- Biohope Scientific Solutions for Human Health, S.L.
Renal Transplant Rejection, Fibrosis
Mesenchymal Stromal Cell Therapy in Renal Recipients
This study will test the hypothesis that MSCs in combination with Everolimus facilitate Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections compared to standard tacrolimus dose.
- Trial name
- MSCs (NCT02057965)
- Testing
- Mesenchymal Stromal Cells
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Antibody-Mediated Rejection (AMR)
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure.
- Trial name
- NCT07613359
- Testing
- Mezagitamab
- Where
- 35 sites in United States, China and 3 more
- Volunteers
- 36 people
- Sponsor
- Takeda
Transplant Rejection, Kidney Transplantation
Study of Tolerant Kidney Transplant Recipients
The purpose of this multi-center (observational) registry study is to establish a database of clinical and laboratory information that may help to identify any unique characteristics of tolerant participants that differ from…
- Conditions
- Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant
- Trial name
- FACTOR (NCT01338779)
- Where
- 4 sites in United States
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplantation, Mesenchymal Stem Cells
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time.
- Trial name
- NCT03478215
- Testing
- Mesenchymal Stromal Stem Cells (MSCs) Infusion
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The Methodist Hospital Research Institute
Microvascular Inflammation
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI).
- Trial name
- TRANSPIRE (NCT07219043)
- Testing
- Felzartamab
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 81 people
- Sponsor
- Biogen
Renal Transplantation
Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant
Investigate the therapeutic effects of the antioxidant N-acetylcysteine on early outcomes of deceased renal transplant patients.
- Trial name
- NACTX (NCT00994305)
- Testing
- N-acetylcysteine, control
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- University of Sao Paulo General Hospital
Renal Transplant Rejection
Multi-Parametric MRI for Renal Transplantation
The goals of this study are: To optimize and evaluate multiple kidney MRI methods; and To investigate the potential of MRI in the assessment of transplant kidney functions; To achieve these goals, we will perform pilot MRI…
- Trial name
- NCT03192007
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Minnesota
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Renal Transplantation
Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients
Chronic transplant nephropathy and cardiovascular death are the main reasons for loss of transplanted organs after kidney transplantation.
- Trial name
- NCT00204321
- Testing
- sirolimus (drug), mmf (drug)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Muenster
Kidney Transplantation, Renal Transplantation
A Study to Evaluate FK778 in Kidney Transplant Patients
A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients
- Conditions
- Kidney Transplantation, Renal Transplantation, Transplantation, Renal, Transplantation, Kidney
- Trial name
- NCT00189735
- Testing
- FK778
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 364 people
- Sponsor
- Astellas Pharma Inc
Prevention of Acute Rejection After Kidney Transplantation
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant
The aim of the study is to evaluate the safety and efficacy of equimolar conversion from MMF to enteric-coated mycophenolate sodium, in renal transplant patients receiving cyclosporine.
- Trial name
- NCT00171379
- Testing
- Enteric-Coated Mycophenolate Sodium
- Volunteers
- 162 people
- Sponsor
- Novartis
Chronic Antibody-mediated Rejection (cABMR)
Allogeneic Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation
Kidney transplantation is the best treatment for end-stage chronic kidney disease (CKD), improving survival and quality of life, while reducing treatment costs.
- Trial name
- SCARR (NCT06886646)
- Testing
- Allogeneic Mesenchymal Stromal Cell Therapy
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody Mediated Rejection of Kidney Transplant
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an…
- Trial name
- NCT02936479
- Testing
- C1-INH (Berinert)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health